A selective ASK1 inhibitor, selonsertib (GS-4997), has recently been tested as therapy for NASH in a phase 2 clinical trial (NCT02466516), and patient outcomes were encouraging. Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.